GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
3 days ago · The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard treatment. A phase 3 study in newly diagnosed transplant-ineligible multiple ...
GSK will pull Blenrep from US market after failed trial
Nov 11, 2024 · GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US...
GSK hails progress for withdrawn blood cancer drug - Financial …
4 days ago · Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of ...
GSK announces Blenrep met key secondary endpoint in DREAMM …
4 days ago · GSK announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
4 days ago · GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC) has ...
Blenrep results ‘transformative’, GSK says | The Pharmaletter
3 days ago · GSK announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head Phase III trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. Data to be shared with regulators
Blenrep shows overall survival benefit in head-to-head DREAMM …
4 days ago · About Blenrep. Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a ...
Is GSK’s Blenrep heading for a renaissance? | pharmaphorum
Nov 10, 2024 · Outperforming Darzalex – an $8 billion-a-year blockbuster – is a major boost to GSK’s hopes for Blenrep, which had been all but written off by market watchers after the DREAMM-3 result.
After withdrawal, GSK touts another Blenrep combo win as …
Mar 7, 2024 · In patients with previously treated multiple myeloma, Blenrep beat Takeda’s Velcade in their respective combinations with Bristol Myers Squibb’s Pomalyst and the corticosteroid dexamethasone, GSK...
GSK provides an update on Blenrep (belantamab mafodotin …
Nov 22, 2022 · GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA).
- Some results have been removed